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Objectives: Interleukin 18 (IL18) is an interferon (IFN)-gamma-inducing factor and a proinflammatory and proathero-
genic cytokine. IL18 binding protein (IL18-BP) functions as an IL18 inhibitor. This study was designed to investigate
whether systemic administration of IL18-BP could inhibit neointimal hyperplasia and arterial lipid deposition.
Methods: New Zealand white, male rabbits were fed with a 21% fat, 0.15% cholesterol diet. The left superficial femoral
artery (SFA) was de-endotheliazed with a 2F arterial embolectomy catheter. IL18-BP (5 g, 10 g, or 25 g), or 0.9%
saline (control) was administered by i.v. bolus during surgery. Rabbits were followed-up at 2 and 4 weeks. Intima-media
(I/M) and lumen-whole artery (L/A) area ratios, and luminal areas were measured. Serum lipid levels, liver enzymes, and
kidney function were evaluated. Inflammatory cells were quantified and further verified with immunohistofluorescence
staining. The extent of lipid deposition in the artery wall was quantified with Oil Red O (ORO) staining employing Zeiss
AxioVision 4.6.3. Image analysis software. Lipid laden cells including macrophages were evaluated by transmission
electron microscopy (TEM).
Results: Intravenous IL18-BP 5 g, 10 g, and 25 g significantly reduced I/M ratios compared with the control group
at both 2 and 4 weeks. There was no significant difference between the 5 g and 10 g dose groups. However, at 10 g,
IL18-BP significantly increased L/A ratio more than either the 5 g IL18-BP or control groups. The high fat diet caused
significant elevation of serum lipids at 4 and 6 weeks. IL18-BP had no effect on blood lipid levels. Lipid deposit in the
thoracic aorta of the control group at 6 weeks was more than at 4 weeks (P .025). Administration of IL18-BP inhibited
the lipid deposition at 4 weeks (not significant) and 6 weeks (P  .012 to .008) compared with its control group. Lipid
laden macrophages (foam cells), as well as endothelial cells and smooth muscle cells were seen in the descending thoracic
aorta after 6 weeks of a high fat diet by ORO, immunohistofluorescence staining, and TEM. The lipid laden cells were not
seen in either of IL18-BP groups. IL18-BP 10 g significantly inhibited mono/macro adherence and infiltration in the
SFA after balloon-injury at 2 weeks after surgery.
Conclusion:A single intravenous dose of IL18-BP significantly decreased arterial neointimal hyperplasia, improved lumen
to artery ratio after balloon-injury and also prevented arteriosclerosis progression. (J Vasc Surg 2008;47:1048-57.)
Clinical Relevance: A single intravenous dose of IL18BP decreased neointimal hyperplasia and improved arterial L/A
ratios in an atherosclerotic balloon-injury animal model. These preliminary results suggest that IL18BP may be a
promising molecular approach to inhibit neointimal hyperplasia and arteriosclerosis progression following coronary and
peripheral angioplasty.Over the past decade, atherosclerosis has been recog-
nized as a complex inflammatory and immune response
disease mediated by cytokines and chemokines at both
the systemic and local levels.1 Both in vitro and in vivo
studies have demonstrated that the cytokine IFN- is
important in atherogenesis.2-4 Interleukin 18 (IL18), a
member of the IL-1 cytokine family, is a potent IFN-–
inducing factor.5,6 It was first found in Kupffer cells and
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1048MØ,5 and later in osteoblasts,7 chondrocytes,8 and ker-
atinocytes.9 Expression of interleukin-18 was also de-
tected in human atherosclerotic plaques and was related
to plaque instability.10 In a rat carotid artery angioplasty
model using high density oligonucleotide micro array
(Affymetrix) and real time quantitative RT-PCR, we
have shown that IL18 gene expression was upregulated
starting at day 1, peaking at day 4, and lasting to day 14
following angioplasty.11
Several investigators have shown that IL18 is a pro-
inflammatory and pro-atherogenic cytokine.12-17 Recently,
IL18 has also been demonstrated to induce rat aortic
smooth muscle cell (SMC) proliferation18 and human cor-
onary artery SMC migration.19 Therefore, IL18 is also a
promitogenic cytokine.
IL18 binding protein (IL18-BP) is a constitutively
expressed and secreted protein and functions as an IL18
inhibitor.20,21 It was shown that in vivo electrotransfer of
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prevented fatty streak development in the thoracic aorta of
apoE knockout mice and slowed progression of atheroscle-
rotic plaque development.22 Maffia et al reported that
neutralizing IL18 with anti-rat IL18 IgG significantly re-
duced neointimal formation in a nonatherosclerotic rat
carotid artery balloon injury model.23 The present study
was designed to determine if the systemic administration of
IL18-BP could inhibit neointimal hyperplasia and arterial
fatty streak development in an atherosclerotic rabbit femo-
ral artery balloon angioplasty model.
METHODS AND MATERIALS
This study was approved by The Animal Care and Use
Committee of the University of Massachusetts Medical
School. All animal procedures were in accordance with the
Guide for the Care and Use of Laboratory Animals.24
Atherosclerotic animal model: male New Zealand
white (NZW) rabbits (body weight 3.50  25 kg; Harlan,
Indianapolis, Ind) were fed with a high fat diet containing
21% fat, 0.15% cholesterol (5TKW, TestDiet Co, Rich-
mond, Ind), which was continued throughout the study.
After 2 weeks the rabbits were subjected to surgery. Serum
lipid levels, liver and kidney functions were evaluated prior
to starting the high fat diet and then on the day of surgery,
2 weeks later, and at termination.
Surgical procedure
New Zealand rabbits were intubated and anesthetized
using intramuscular ketamine (50 mg/kg,) and xylazine (5
mg/kg), intubated and maintained with inhaled 1% to 2%
Isoflurane. Crystiben (Pencillin G Benzaprine and Penicil-
lin G Procaine) 150,000 units IMwas given preoperatively.
Heparin 100 units/kg was given i.v. 5 minutes before
artery clamping. The left superficial femoral artery (SFA)
was denuded by fully expanding a 2F arterial embolectomy
balloon catheter three times within the SFA.25 Analgesic
buprenorphine (0.03 mg/kg) was given subcutaneously
(SC) prior to surgery and a transdermal fentanyl patch (1/2
to one of 25 g/hr patch) was placed on the back skin for
2 days postoperatively for pain relief. The animals were
randomly selected to receive an i.v. bolus of 0.9% saline
control or IL18-BP recombinant mouse IL18-BPd/Fc
chimera (R&D Systems, Inc., Minneapolis, Minn) at 5 g,
10 g, or 25 g, prior to reconstituting SFA blood flow.
The anti-rabbit IL18-BP is not commercially available. The
amino acid sequence of mouse IL18-BP is 90.6% identical
to rat. For uniformity, matched control and IL18-BP
group animals underwent surgery on the same day under
the same conditions. The rabbits were followed-up at 2
weeks and 4 weeks postoperatively.
Specimen collection
On the day of termination, the animals were anesthe-
tized and intubated as described above. Heparin 100
units/kg was administrated intravenously. Both femoral
arteries were harvested following antegrade cannulation
and perfusion with 0.9% saline at 110 to 120 mm Hgpressure, followed by perfusion fixation with 10% buffered
formalin. Segments of the experimental arteries includ-
ing the common femoral, superficial femoral, and popli-
teal arteries were removed en bloc and fixed in 10%
buffered formalin. Bilateral SFA samples (about 2.5 cm
in length) were cross-sectioned into three segments:
proximal, middle, and distal thirds. These segments were
processed for paraffin embedding, sectioning 5 m
thick, and hematoxylin-eosin (HE) staining. The descend-
ing thoracic aortas were removed and fixed in 10% buffered
formalin. The ascending aortas were snap frozen with op-
timum cutting temperature (OCT) compound (Tissue-
Tek, Sakura Finetek, Torrance, Calif) and kept at 80oC
for cryo-section. Specimens were identified by the rabbit
ID number only and all subsequent morphometric area
measurements and analyses were performed in a blinded
fashion.
Histology
Two representative HE stained cross-sections of the
proximal, middle, and distal superficial femoral artery were
analyzed using a digital imaging computerized planimetry
equipped a cooled CCD camera (Roper Scientific, Prince-
ton Instruments Inc., Acton, Mass) attached to an inverted
microscope (Olympus IX-70, Olympus Corp., Tokyo, Ja-
pan). The images were analyzed using imagingJ software.
The lumen, intima, media, and whole artery areas were
measured. The area ratios of intima to media (I/M), and
lumen to whole artery (L/A) were calculated.
Blood laboratory parameters. The serum total cho-
lesterol, high-density lipoprotein (HDL), low-density li-
poprotein (LDL), triglyceride, very low-density lipoprotein
(VLDL), serum glutamic oxaloacetic transaminase
(SGOT), serum glutamic pyruvic transaminase (SGPT),
blood urea nitrogen (BUN), and creatinine levels were
measured prior to starting the high fat diet, 2 weeks later on
the day of surgery and at termination.
Oil Red O (ORO) staining. The extent of fatty streak
was evaluated in the descending thoracic aorta, which had
been fixed in 10% buffered formalin. A segment of the
descending aorta was longitudinally opened, washed with
Milli-Q water (Millipore Corp., Billerica, Mass). After re-
moval of the adventitia, the artery was pined on a cork
board. The exposed lumen was processed for ORO (Cat
No K043, Poly Scientific R&D Corp, Bay Shore, NY)
staining. The images were taken with a Leica light ste-
reomicroscope at 0.42 and 3.25. Lipid deposit on the
inner surface was quantified using Zeiss AXIOVision soft-
ware. The cross-sections (5 m) of the descending tho-
racic aorta were also cryo-sectioned and subjected to
ORO staining.
Immunohistofluorescence staining. The cryo-sections
of the descending thoracic aorta were subjected to immu-
nofluorescence staining for identification of lipid laden cells
including macrophages or foam cells.
The SFA paraffin blocks were sectioned for immuno-
histofluorescence staining to identify inflammatory cells
and to confirm the findings on HE stain slides. Neutrophils
02, a
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mouse anti-rabbit antibody MCA805 (AbD Serotec, Ra-
leigh, NC) and visualized with second antibody Rhoda-
mine Red-X-conjugated AffiniPure goat anti-mouse IgG
(HL) (Jackson ImmunoResearch Laboratories, West
Grove, Penn). Macrophages were identified with mono-
clonal mouse anti-rabbit macrophage RAM11 primary
antibody (DakoCytomation, Inc., Carpinteria, Calif),
and visualized with fluorescein (FITC)-conjugated
AffiniPure F(ab’) fragment goat anti-mouse IgG (HL)
(Jackson ImmunoResearch Laboratories).25 The nucleus
was stained with DAPI, which was contained in
VECTASHIELD mounting medium (Vector Laborato-
ries, Burlingame, Calif). Images were taken with Zeiss
imager.M1 microscope.
Evaluation of inflammatory cells. The HE stained
cross-section of SFA samples were quantified for polymor-
phonuclear neutrophils (PMN), lymphocytes, monocytes/
macrophage (mono/macro) adhesion, and infiltration with
microscopy, Zeiss imager.M1, under 20. The inflamma-
tory cells were counted from the whole field of the sample
section. There were three SFA samples for each time period
Fig 1. A, Immunofluorescence stain of cross-section
angioplasty. PMN (red), mono/macro (green), and nucle
reaction of rabbit femoral artery 2 weeks and 4 weeks aft
or time on PMN and lymphocytes. For mono/macro IL
and IL18-BP 5 g and 25 g groups (P  .0002,  .00(2 weeks and 4 weeks) and for each treatment group(control, IL18-BP 5 g, 10 g, and 25 g). Each artery
contains three segments (proximal, middle, distal) each of
which was duplicated. Therefore, each data point in the Fig
1, B represents the mean of 18 sections. The inflammatory
cells were further verified with immunohistofluorescence
staining.
Transmission electron microscopy (TEM). The
segments of the descending thoracic aorta after 6 weeks
high fat diet with or without IL18-BP 10 g were evalu-
ated with TEM for identification of lipid laden cells or fatty
streak.25
Statistical analysis
The effects of treatment, follow-up time, artery seg-
ment, and so on were evaluated by analysis of variance
(ANOVA) for mixed models26 (ie, factorial repeated mea-
sures design) by restricted maximum likelihood (REML).
In the presence of significant main or interaction effects,
pairwise comparisons were performed using the Tukey-
Kramer multiple comparisons procedure27 using the actual
fitted covariance structure. The distributional characteris-
tics of the outcome variables were assessed using the
bit femoral artery 2 weeks and 4 weeks after balloon
lue). Bar 5 m. B,Quantification of inflammatory cell
lloon-injury. There were no significant effects of dosage
P 10 g group was significantly less than control group,
nd  .0036, respectively) at 2 weeks.of rab
us (b
er ba
18-BKolmogorov-Smirnov goodness-of-fit test for normality on
arotid
 0.0
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SAS 9.1.3 Proc Mixed and SPSS 14 statistical softwares.
The results of lumen area, neointima area, media area,
whole artery area, neointima to media (I/M) ratio, and
lumen to artery (L/A) ratio, are expressed as the mean 
SEM of three to five experimental animals. The effect of
ratios or lumen area vs artery segment, treatment, and
length of follow-up were evaluated. Differences were con-
sidered significant at the 95% confidence level (P  .05).
The effects of dosage and time on PMN, lyphocytes,
and mono/macro were evaluated by generalized linear
mixed modeling (GLMM) assuming a negative binomial
distribution,28 which allowed for the effects of both cate-
gorical and continuous covariates such as time and dosage
modeling them either as groups or as linear relationships
with separate slopes for groups. Models were fit by re-
strictedmaximum likelihood estimation using the SAS Proc
GLIMMIX procedure.29 Models were constructed by first
fitting saturated models and then eliminating higher order
interaction terms that were not significant until a parsimo-
nious model resulted that contained significant factors and
covariates as determined by the type III fixed effects tests
Fig 2. Effect of IL18-BP on neointima to media area ra
and luminal area of the femoral artery 2 weeks and 4 w
represents 18 to 30 sections of the left balloon-injured c
Table. Histomorphometric measurement areas of lumen,
Group Lumen (mm2) Neointim
2 wk postop
Control
0.9% saline 1.75  0.30 0.43
IL18-BP
5 g 1.11  0.22 0.23
10 g 2.07  0.30 0.26
25 g 1.74  0.32 0.13
4 wk postop
Control
0.9% saline 1.90  0.19 0.51
IL18-BP
5 g 1.55  0.24 0.34
10 g 2.02  0.18 0.41
25 g 2.54  0.20 0.32for those effects. In the presence of significant differencesamong means, pairwise comparisons were made using
Tukey’s Honestly Significant Difference (HSD) test utiliz-
ing the estimated covariance matrix to account for corre-
lated observations.
RESULTS
A total of 50 NZWmale rabbits were used in this study
with average body weight 3.53  0.34 kg. Sixteen rabbits
were fed an atherogenic chow but did not undergo angio-
plasty. The treatment group was composed of 29 animals
that were also fed an atherogenic diet and underwent a left
SFA angioplasty and received 0.9% saline control or
IL18-BP at three different dose levels. Five rabbits, either
from control group or IL18-BP groups, were excluded that
died of anesthetic complications.
Histology
The morphologic appearance of the cross-section of
left femoral artery following balloon-injury is shown in
Fig 1. The circumferential neointima was obvious in the
saline control group by postoperative week 2 and 4. Visual
inspection shows that the neointimal thickness decreases
/M ratio), lumen to whole artery area ratio (L/A ratio),
after balloon-injury. Mean  SEM, N  3-5. Each bar
artery from three to five animals.
ntima, media, and whole artery (mean  SEM)
m2) Media (mm2) Whole artery (mm2)
6 0.46  0.06 2.75  0.34
4 0.37  0.04 1.81  0.40
3 0.47  0.03 3.06  0.30
2 0.39  0.05 1.96  0.25
4 0.44  0.03 2.88  0.23
7 0.38  0.03 2.43  0.20
3 0.55  0.02 3.01  0.16
4 0.41  0.07 3.27  0.20tio (I
eeksneoi
a (m
 0.0
 0.0
 0.0
 0.0
 0.0
 0.0
 0.0with systemic administration of IL18-BP. Leukocytes ad-
2 wee
rea on
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can be seen in Fig 1B at 10.
Morphometric analysis. The results of neointima for-
Fig 3. Blood lipid panel before and after
Fig 4. A,Lipid deposition on the inner surface of rabbit de
and 6weeks high fat diet (A,ORO stain); Calciumdepositio
high fat diet (B,HE stain).C,Percentage area of lipid depos
aorta.Data represent the percentage of total lipid deposition amation and luminal preservation are shown in Fig 2. TheTable lists the data for lumen, neointima, media and whole
artery areas. Intima to media (I/M) ratio following
balloon-injury the I/M ratio decreased significantly both at
ks, 4 weeks, and 6 weeks of high fat diet.
ing thoracic aorta with andwithout IL18-BP after 4weeks
he ascending thoracic aorta without IL18-BP after 4weeks
n the inner surface of a segment of the descending thoracic
4.38 cm2 surface. Two animals of each groupwere analyzed.scend
n in t
ition o2 weeks and 4 weeks after surgery in the IL18-BP groups
dothe
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respectively). Among the IL18-BP groups, there was no
statistical difference between 5 g vs 10 g, but the higher
Fig 5. A, ORO staining of cross-section of rabbit desc
laden cells are seen after 6 weeks high fat diet. N
B, Immunofluorescence stain of cross-section of rabbi
macrophage (green), and nucleus (blue). Upper row,
(22), and SMC (asterisk). Bottom row, merged im
C, Transmission electron microscopy (TEM) image of c
diet without IL18-BP. Two Macrophages are seen tha
between endothelial cells, and the other one beneath endose of 25 g group showed a significant decrease in theI/M ratio compared with the lower dose groups. No
significant difference was found between the three segment
locations of the artery. The effects of different dosages of
g thoracic aorta. Lipid (red) and nucleus (blue). Lipid
id laden cell is seen in IL18-BP treatment groups.
ending aorta 6 weeks after high fat diet. Lipid (red),
laden macrophages (2 black, white), endothelial cells
of two images of upper rows identifying foam cells.
ection of rabbit descending aorta 6 weeks after high fat
lipid laden (foam cells), one is undergoing diapedesis
lium. (8000).endin
o lip
t desc
Lipid
age
ross-s
t haveIL18-BP (5 g, 10 g, and 25 g) on the percentage
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40.2%, 45.5%, and 66.2% at 2 weeks postop and 17.1%,
30.6%, and 56.3% at 4 weeks, respectively (Fig 2).
Lumen to whole artery (L/A) ratio. IL18 10 g
significantly increased the L/A ratio compared with the
control group and to the IL18-BP 5 g group at both 2
weeks and 4 weeks. There was no statistical difference
between 5 g and control. IL18-BP 25 g did not further
increase the L/A ratio compared with IL18-BP 10 g
group.
Lumen area measurements did not show any clear
pattern of significance at different time points or among
different experimental groups. Because of variations in the
diameter of the superficial femoral artery, even between
rabbits of the same weight, we found L/A ratio to be more
representative than simple measurements of luminal area.
Atherosclerosis evaluation
Blood lipid profile. Blood cholesterol, LDL, HDL,
VLDL, and cholesterol to HDL ratio were not significantly
increased after consuming 2 weeks of a high fat diet.
However, they were significantly increased after 4 weeks,
and increased continuously at 12 weeks (P .01). Triglyc-
eride levels were decreased at 2 weeks, 4 weeks, and 6 weeks
compared with before high fat diet (P  .02, .005, and
.066, respectively). There were no statistical differences of
blood lipids between 0.9% saline control and IL18-BP
treatment groups (Fig 3).
Lipid deposition. With ORO staining lipid deposi-
tion in the inner surface of the descending thoracic aorta
was seen as small red dots in the control group after 4 weeks
of a high fat diet. The lipid deposition was further increased
Fig 5C.with higher density and bigger dot size at 6 weeks (Fig 4,A). IL18-BP 5 g, 10 g, or 25 g decreased fat deposi-
tion at 4 weeks (Fig 4, A, upper row) and at 6 weeks (Fig 4,
A, bottom row).
Calcium deposits were seen in the ascending thoracic
aorta at 4 weeks. (Fig 4, B, HE stain).
The results of quantification of the extent of lipid
deposition on the inner surface of a segment of the de-
scending thoracic aorta are shown in Fig 4C, which dem-
onstrates the percentage of total lipid deposition area on
4.38 cm2 surface. Two animals of each group were ana-
lyzed. Lipid deposition for the control group at 6 weeks was
significantly greater than control at 4 weeks as well as each
of IL18-BP treatment groups at 4 and 6 weeks. IL18-BP
reduced lipid deposition by 32.3% to 78.5% compared with
its control. There were no significant differences between
different dosages of IL18-BP treatment.
Fig 5A demonstrates the ORO staining of the descend-
ing thoracic aorta after 4 and 6 weeks of a high fat diet. At
6 weeks, the lipid is clearly seen in the mono/macro,
endothelial cells and smooth muscle cells, but it is not seen
in the IL18-BP treatment groups.
Images of ORO and immunohistofluorescence stained
cross-sections of the descending thoracic aorta after 6
weeks of a high fat diet are shown in Fig 5B. There were
lipid laden macrophages (foam cells), endothelial cells, and
SMC. Transmission electron microscopy of the same spec-
imen showed one macrophage containing lipid in a plasma
cell (foam cell) undergoing diapedesis between endothelial
cells, and another beneath the endothelium. Fig 5C
(8000). There were no lipid laden cells seen in the
descending thoracic aorta treated with IL18-BP 10 g
(image not shown).
Liver and kidney functions. The high fat diet had no
effect on liver function after 4 weeks as measured by SGOT
and SGPT. However, SGOT levels were significantly ele-
vated with high dose of IL18-BP 25 g at 6 weeks com-
pared with pre-high fat diet (P  .0321). IL18-BP 5 g
and 10 g had no significant liver impairing effect. SGPT
was mildly elevated (NS) (Fig 6). The gross appearance of
the liver appeared normal at the time of termination. There
was no impairment of kidney function as measured by BUN
Fig 6. Serum glutamic oxaloacetic transaminase (SGOT) and
serum glutamic pyruvic transaminase (SGPT) level. Before and
after 6 weeks of high fat diet with and without IL18-BP. SGOT
was significantly elevated with IL18-BP 25 g.and creatinine.
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staining for PMN, lymphocytes and mono/macro of the
cross-sections of the SFA after balloon angioplasty are
shown in Fig 7A. The quantitative cell counts are shown in
Fig 7B. The administration of IL18-BP did not significantly
affect the presence of PMN and lymphocytes at any time
point compared with the control group. At 2 weeks,
IL18BP 10 g, however, significantly decreased mono-
cytes compared with the control and the other two treat-
ment groups (P  .0002,  .0002 and .0036, respec-
tively). At 4 weeks, mono/macro was less in IL18-BP 5 g
and 10 g groups (NS).
DISCUSSION
IL18, a potent IFN--inducing cytokine5,6 is important
in the development of atherosclerosis.12-17 It also induces
SMC proliferation18 and migration.19 IL18 gene expression
was shown to elevate after balloon angioplasty11,23 and de-
tected in human atherosclerotic plaques and in stabilized
plaque.10 Therefore, inhibition of IL18 would be an efficient
approach in the treatment of clinical atherosclerotic cardiovas-
cular patients. A molecule that has biologic functions of both
inhibiting neointima formation and atherosclerotic progres-
Fig 7. A and B, Microphotograph of representative c
without IL18-BP in an atherosclerotic rabbit model. Ori
microns.sion would be of great clinical utility.The pro-atherosclerotic signaling pathways for cytokine
IL18 involves a key role for mature IL18 in the regulation of
IFN- synthesis.12,16 Additionally, IL18 also augments the
production of various other mediators implicated in athero-
genesis such as, cytokines IL-1ß and the intracellular adhesion
molecule (ICAM)-1.13,15 Furthermore, IL18 activates Th1
responses, which dominate during human atherogenesis14
and the Th1 lymphocyte subpopulation express the receptor
for IL18.17 IL18 is therefore a proinflammatory and
proatherogenic cytokine. The mechanism of action of IL18
involves binding of the heterodimeric IL18 receptor complex,
comprised of the IL-1 receptor-related protein (IL-1Rrp),
termed IL18R	, and the IL-1 receptor accessory protein-like
(IL-1RacPL), termed IL18Rß.30-32 Overexpression of both
IL18 and IL18R	/ß were found within human atheroma in
situ compared with normal arterial tissue, and the ligation
of the receptor on cultured endothelial cells (ECs),
smooth muscle cells (SMC), and macrophages, and in
human artery SMC.33 It is therefore reasonable to expect
that systemic blockage of IL18 using IL18-BP may
reduce the proatherogenic response.
Several signaling pathways for the IL18 pro-mitotic
mechanism have been identified.18,19,23 It was reported
sections of femoral artery after balloon-injury with and
magnifications 4 (A), 10 (B). HE stain, Bar  100ross-
ginalthat IL18 induced CXCL16 expression in rat aortic smooth
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kinase, tumor necrosis factor receptor-associated factor 6,
c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-
terminal kinase, and activator protein-1 signaling18 and
that induction of human coronary artery SMC migration
was dependent on NF-kB- and AP-1-mediated matrix
metalloproteinase-9 expression.19 Maffia et al studied the
expression of IL18, IL18R	/ß, IFN, IL-6, and IL-8
mRNA in rat carotid arteries after balloon angioplasty using
real time reverse-transcription polymerase chain reaction
(RT-PCR). All of these cytokines/chemokines were up-
regulated after angioplasty.23
IL18 binding protein (IL18-BP) decreases endoge-
nous IL18 activity by reducing IL18 induction of IFN-
mediated responses in vitro34 and in mice.22 Four human
and two mouse isoforms were successfully assessed for
binding and neutralization of IL18 biological activi-
ties.20,21 In an apoE knockout mice Mallat et al22 showed
that IL18-BP plasmid prevented fatty streak and stabilized
the atherosclerotic plaque. They have also shown that a
serum of dilution of 1:90 from the transferred mice com-
pletely abrogated IFN production indicating an in vivo
inhibitory activity against IL18. In a nonatherosclerotic rat
carotid artery balloon injury model Maffia et al23 neutral-
ized IL18 with anti-rat IL18 IgG reducing neointimal
formation, inhibiting IFN, IL6, and reducing IL18
mRNA expression at day 7, andNF-kB activation at day 14.
The present study showed that following 6 weeks of a
high fat diet, containing 21% fat and 0.15% cholesterol, dis-
tinct lipid laden macrophages (foam cells), endothelial cells,
and smooth muscle cells developed in the thoracic aorta of
control animals but not in either of the IL18-BP treated
groups. At the same time, the administration of IL18-BP had
no effect on serum lipid levels. Mallat et al23 also found that
serum cholesterol and HDL levels were no different between
IL18-BP and control group in apoE knockout mice. Our
results and those ofMallat suggest that the atherogenicmech-
anism of action of IL18-BP is from a direct inhibition of IL18
binding to IL18 receptors, rather than an indirect response to
an increase in serum lipid and cholesterol levels.
This study also found that a single dose of IL18-BP
produced a significant decrease in neointimal hyperplasia 2
and 4 weeks after balloon-injury of the superficial femoral
artery, measured by intima to media ratios. Furthermore, the
reduction was related to the dose of IL18-BP. These findings
confirm the findings of others23 that IL18-BP blocks the
inflammatory and mitogenic properties of IL18 that are the
key to the development of neointimal hyperplasia.
The accelerated development of hyperplasia, which we
observed in this animal model, is in contrast to the usual
time course for the development of neointimal hyperplasia
in humans, which ranges from months to a year or more. If
IL18-BP proves to be an effective inhibitor of hyperplasia in
humans, would this short-time course limit its applicability
or is there a means to extend the up-regulation of mRNA to
maintain suppression of hyperplasia? Would repeated doses
of IL18-BP be necessary to prolong the inhibition of the
hyperplasia? What are the rabbit blood IL18 and IL18BPlevels? The answers to these questions will come from a
more thorough understanding of the pharmacoactivity of
IL18-BP and its potential for long-term inhibition of hy-
perplasia and atherosclerosis.
CONCLUSIONS
This study demonstrated that a single intravenous dose of
IL18-BP significantly decreased arterial neointimal hyperpla-
sia and improved lumen to artery ratio after balloon-injury and
also prevented arteriosclerosis progression. If the safety and
efficacy of IL18-BP can be confirmed in other animal models
IL18-BP could be of potential benefit to inhibit neointimal
hyperplasia following coronary and peripheral angioplasty.
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